Noticias de Farmacia de Formulación Magistral

As demand for IV therapy climbs, clinics are expanding their services to keep up. But with that growth comes logistical challenges. One of the most common pain points we hear from clinic managers? Inventory management. From overstocked vitamin additives to missing ingredients and inconsistent supply levels, juggling a full IV therapy inventory can quickly become

The IV bag shortage has become a pressing challenge for healthcare providers, disrupting treatments and straining resources nationwide. This shortage, exacerbated by Hurricane Helene’s impact on a major production facility, highlights vulnerabilities in the medical supply chain and underscores the need for alternative solutions. As hospitals adapt to these constraints, intramuscular (IM) therapy emerges as

At Olympia, we understand the practicality and importance of both 503A and 503B compounding pharmacy capabilities. Each of these designations of compounders has an important role to fill in today’s compounding landscape. With two separate, state-of-the-art facilities, we support both patient-specific and office-use needs across the U.S. This enables our customers to comply with all

What Is an FDA Outsourcing Facility? In 2013, The U.S. Food and Drug Administration signed into law The Drug Quality and Security Act, which created a new section called 503B in the Federal Food, Drug and Cosmetic Act (FDCA). This act enables a compounding pharmacy to become a 503B outsourcing facility. The legal definition of

Understanding 503B Pharmacies Olympia Compounding Pharmacy understands the importance of providing both patient-specific and office-use needs across the country. That’s why we’re equipped with two separate, state-of-the-art facilities — one to fulfill 503A compounding pharmacy needs and the other for 503B. Learn more about the difference between 503A and 503B compounding pharmacies in our TikTok